Literature DB >> 12601640

In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?

Jonas Burén1, Stina Lindmark, Frida Renström, Jan W Eriksson.   

Abstract

Chronic hyperglycemia promotes the development of insulin resistance. The aim of this study was to investigate whether cellular insulin resistance is secondary to the diabetic state in human type 2 diabetes. Subcutaneous fat biopsies were taken from 3 age-, sex-, and body mass index (BMI)-matched groups with 10 subjects in each group: type 2 diabetes patients with either good (hemoglobin A(1c) [HbA(1c)] < 7%, G) or poor (HbA(1c) > 7.5%, P) metabolic control and healthy control subjects (C). Insulin action in vitro was studied by measurements of glucose uptake both directly after cell isolation and following a 24-hour incubation at a physiological glucose level (6 mmol/L). The relationship with insulin action in vivo was addressed by employing the euglycemic clamp technique. Freshly isolated fat cells from type 2 diabetes patients with poor metabolic control had approximately 55% lower maximal insulin response (1,000 microU/mL) on glucose uptake (P <.05) compared to C. Cells from P were more insulin-resistant (P <.05) than cells from G at a low (5 microU/mL) but not at a high (1,000 microU/mL) insulin concentration, suggesting insulin insensitivity. However, following 24 hours of incubation at physiological glucose levels, insulin resistance was completely reversed in the diabetes cells and no differences in insulin-stimulated glucose uptake were found among the 3 groups. Insulin sensitivity in vivo assessed with hyperinsulinemic, euglycemic clamp (M-value) was significantly associated with insulin action on glucose uptake in fresh adipocytes in vitro (r = 0.50, P <.01). Fasting blood glucose at the time of biopsy and HbA(1c), but not serum insulin, were negatively correlated to insulin's effect to stimulate glucose uptake in vitro (r = -0.36, P =.064 and r = - 0.41, P <.05, respectively) in all groups taken together. In the in vivo situation, fasting blood glucose, HbA(1c), and serum insulin were all negatively correlated to insulin sensitivity (M-value; r = -0.62, P<.001, r= -0.61, P<.001, and r = -0.56, p <.01, respectively). Cell size, waist-to-hip ration (WHR), and BMI correlated negatively with insulin's effect to stimulate glucose uptake both in vitro (r = -0.55, P <.01, r = -0.54, P <.01, and r = -0.43, P <.05, respectively) and in vivo (r = -0.43, P <.05, r = -0.50, P <.01, and r = -0.36, P <.05, respectively). Multiple regression analyses revealed that adipocyte cell size and WHR independently predicted insulin resistance in vitro. Furthermore, insulin sensitivity in vivo could be predicted by fasting blood glucose and serum insulin levels. We conclude that insulin resistance in fat cells from type 2 diabetes patients is fully reversible following incubation at physiological glucose concentrations. Thus, cellular insulin resistance may be mainly secondary to the hyperglycemic state in vivo. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601640     DOI: 10.1053/meta.2003.50041

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  13 in total

1.  Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'.

Authors:  M Lundgren; M Svensson; S Lindmark; F Renström; T Ruge; J W Eriksson
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

2.  Modest hyperglycemia prevents interstitial dispersion of insulin in skeletal muscle.

Authors:  Cathryn M Kolka; Ana Valeria B Castro; Erlinda L Kirkman; Richard N Bergman
Journal:  Metabolism       Date:  2014-11-04       Impact factor: 8.694

3.  Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans.

Authors:  B Meissburger; L Stachorski; E Röder; G Rudofsky; C Wolfrum
Journal:  Diabetologia       Date:  2011-03-25       Impact factor: 10.122

4.  Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review of the Literature.

Authors:  Richard Sotorník; Roguel Suissa; Jean-Luc Ardilouze
Journal:  Clin Diabetes       Date:  2022

5.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

Authors:  Aurora Merovci; Carolina Solis-Herrera; Giuseppe Daniele; Roy Eldor; Teresa Vanessa Fiorentino; Devjit Tripathy; Juan Xiong; Zandra Perez; Luke Norton; Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 6.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Effects of high glucose on caveolin-1 and insulin signaling in 3T3-L1 adipocytes.

Authors:  Sara Palacios-Ortega; Maider Varela-Guruceaga; J Alfredo Martínez; Carlos de Miguel; Fermín I Milagro
Journal:  Adipocyte       Date:  2015-12-08       Impact factor: 4.534

8.  Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.

Authors:  Aurora Merovci; Muhammad Abdul-Ghani; Andrea Mari; Carolina Solis-Herrera; Juan Xiong; Giuseppe Daniele; Devjit Tripathy; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2016-01-14       Impact factor: 5.958

9.  Insulin action in adipose tissue in type 1 diabetes.

Authors:  Francisco Arrieta-Blanco; Jose Ignacio Botella-Carretero; Pedro Iglesias; José Antonio Balsa; Isabel Zamarrón; Cristina De la Puerta; Juan José Arrieta; Francisco Ramos; Clotilde Vázquez; Adela Rovira
Journal:  Int J Gen Med       Date:  2011-02-22

10.  Alterations in heart rate variability during everyday life are linked to insulin resistance. A role of dominating sympathetic over parasympathetic nerve activity?

Authors:  Maria K Svensson; Stina Lindmark; Urban Wiklund; Peter Rask; Marcus Karlsson; Jan Myrin; Joel Kullberg; Lars Johansson; Jan W Eriksson
Journal:  Cardiovasc Diabetol       Date:  2016-06-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.